Mivobulin free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205980

CAS#: 122332-18-7 (free base)

Description: Mivobulin, also known as CI-980, is a synthetic colchicine analogue with potential antineoplastic activity. Mivobulin isethionate binds to tubulin, thereby inhibiting microtubule polymerization and mitosis.

Chemical Structure

Mivobulin free base
CAS# 122332-18-7 (free base)

Theoretical Analysis

MedKoo Cat#: 205980
Name: Mivobulin free base
CAS#: 122332-18-7 (free base)
Chemical Formula: C17H19N5O2
Exact Mass: 325.1539
Molecular Weight: 325.372
Elemental Analysis: C, 62.75; H, 5.89; N, 21.52; O, 9.83

Price and Availability

Size Price Availability Quantity
Bulk inquiry

Related CAS #: 126268-81-3 (Isethionate)   122332-18-7 (free base)    

Synonym: Mivobulin free base; CI-980; NSC-613863; NSC-635370; NSC-613862; NSC-350386; CI980; NSC613863; NSC635370; NSC613862; NSC350386.

IUPAC/Chemical Name: (S)-ethyl (5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl)carbamate


InChi Code: InChI=1S/C17H19N5O2/c1-3-24-17(23)21-13-9-12-15(16(18)20-13)22-14(10(2)19-12)11-7-5-4-6-8-11/h4-10,19H,3H2,1-2H3,(H3,18,20,21,23)/t10-/m0/s1

SMILES Code: O=C(OCC)NC1=CC2=C(C(N)=N1)N=C(C3=CC=CC=C3)[C@H](C)N2

Appearance: Solid powder

Purity: >98%

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 325.372 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Kunschner LJ, Fine H, Hess K, Jaeckle K, Kyritsis AP, Yung WK. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer Invest. 2002;20(7-8):948-54. PubMed PMID: 12449727.

2: Thomas JP, Moore T, Kraut EH, Balcerzak SP, Galloway S, Vandre DD; Ohio State University Phase II Research Consortium Study.. A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study. Cancer Invest. 2002;20(2):192-8. PubMed PMID: 11901539.

3: Whitehead RP, Unger JM, Flaherty LE, Eckardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Invest New Drugs. 2001;19(3):239-43. PubMed PMID: 11561681.

4: Ryan CW, Shulman KL, Richards JM, Kugler JW, Sosman JA, Ansari RH, Vokes EE, Vogelzang NJ. CI-980 in advanced melanoma and hormone refractory prostate cancer. Invest New Drugs. 2000 May;18(2):187-91. PubMed PMID: 10857996.

5: Bernstein ML, Baruchel S, Devine S, Markoglou N, Wainer IW, Williams M, Blaney S, Moghrabi A, Winick N, Vietti T. Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):494-500. PubMed PMID: 10598660.

6: Patel SR, Burgess MA, Papadopolous NE, Sidhu G, Gray R, Plager C, Jenkins J, Benjamin RS. Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest New Drugs. 1998;16(1):87-92. PubMed PMID: 9740549.

7: Kudelka AP, Hasenburg A, Verschraegen CF, Edwards CL, Meyers CA, Varma D, Freedman RS, Forman A, Conrad CA, Grove W, Grothey A, Kavanagh JJ. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs. 1998 Jun;9(5):405-9. PubMed PMID: 9660537.

8: Pazdur R, Meyers C, Diaz-Canton E, Abbruzzese JL, Patt Y, Grove W, Ajani J. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am J Clin Oncol. 1997 Dec;20(6):573-6. PubMed PMID: 9391543.

9: Markoglou N, Wainer IW. Determination of the anticancer agent CI-980 in plasma by achiral liquid chromatography on a Pirkle-type stationary phase. J Chromatogr B Biomed Sci Appl. 1997 Jun 6;693(2):493-7. PubMed PMID: 9210458.

10: Wright J, Ho PT, Phillips PH, Cheson BD. Clinical Trials. Referral resource Clinical trials using CI-980 (mivobulin isethionate). Oncology (Williston Park). 1997 May;11(5):643-4. PubMed PMID: 9159791.

11: Meyers CA, Kudelka AP, Conrad CA, Gelke CK, Grove W, Pazdur R. Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res. 1997 Mar;3(3):419-22. PubMed PMID: 9815700.

12: Rowinsky EK, Long GS, Noe DA, Grochow LB, Bowling MK, Sartorius SE, Donehower RC. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin Cancer Res. 1997 Mar;3(3):401-7. PubMed PMID: 9815698.

13: Sklarin NT, Lathia CD, Benson L, Grove WR, Thomas S, Roca J, Einzig AI, Wiernik PH. A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Invest New Drugs. 1997;15(3):235-46. PubMed PMID: 9387046.

14: Pérez O, Valenzuela C, Delpón E, Tamargo J. Electrophysiological effects of CI-980, a tubulin binding agent, on guinea-pig papillary muscles. Br J Pharmacol. 1997 Jan;120(2):187-92. PubMed PMID: 9117108; PubMed Central PMCID: PMC1564362.

15: Barbier P, Peyrot V, Dumortier C, D'Hoore A, Rener GA, Engelborghs Y. Kinetics of association and dissociation of two enantiomers, NSC 613863 (R)-(+) and NSC 613862 (S)-(-) (CI 980), to tubulin. Biochemistry. 1996 Feb 13;35(6):2008-15. PubMed PMID: 8639685.

16: Hook KE, Przybranowski SA, Leopold WR. Cellular transport of CI-980. Invest New Drugs. 1996;14(4):341-7. PubMed PMID: 9157068.

17: Bullen WW, Whitfield LR, Walter GA, Brodfuehrer JI. High-performance liquid chromatographic assay for CI-980, a novel 1-deaza-7,8-dihydropteridine anticancer agent, in human plasma and urine. J Chromatogr B Biomed Appl. 1995 Jun 9;668(1):141-51. PubMed PMID: 7550971.

18: Chevalier P, Kuznetsov V, Robinson RB, Rosen MR. Tubulin binding agent CI-980 has positive inotropic and local anesthetic actions. J Cardiovasc Pharmacol. 1994 Jun;23(6):944-51. PubMed PMID: 7523787.

19: de Ines C, Leynadier D, Barasoain I, Peyrot V, Garcia P, Briand C, Rener GA, Temple C Jr. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. Cancer Res. 1994 Jan 1;54(1):75-84. PubMed PMID: 8261466.

20: MacDonald JR, Pegg DG. Extravasation injury potential of CI-980, a novel synthetic mitotic inhibitor. Cancer Chemother Pharmacol. 1993;32(5):365-7. PubMed PMID: 8339386.

Additional Information

  Related CAS#
122332-18-7 (Mivobulin free base)
126268-81-3 (Mivobulin Isethionate)